Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 12/20 | 0.67 |
| ▸ | MMP3 | P08254 | 5/20 | 0.67 |
| ▸ | MMP2 | P08253 | 10/20 | 0.65 |
| ▸ | MMP9 | P14780 | 10/20 | 0.65 |
| ▸ | MMP1 | P03956 | 5/20 | 0.65 |
| ▸ | MMP7 | P09237 | 4/20 | 0.65 |
| ▸ | MMP8 | P22894 | 4/20 | 0.65 |
| ▸ | MMP13 | P45452 | 4/20 | 0.65 |
| ▸ | MMP14 | P50281 | 4/20 | 0.65 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.65 |
| ▸ | MMP15 | P51511 | 1/20 | 0.64 |
| ▸ | MMP16 | P51512 | 1/20 | 0.64 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777098 | 0.94 | ADAM17 (0.67) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4202835 | 0.94 | ADAM17 (0.67) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4203386 | 0.94 | ADAM17 (0.67) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4208520 | 0.94 | ADAM17 (0.69) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4196677 | 0.93 | ADAM17 (0.66) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4202198 | 0.93 | ADAM17 (0.67) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4212314 | 0.92 | ADAM17 (0.65) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4198018 | 0.92 | ADAM17 (0.79) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4200558 | 0.90 | ADAM17 (0.68) | ADAM17MMP3MMP2MMP9MMP1 | |
| SCHEMBL4199445 | 0.89 | ADAM17 (0.65) | ADAM17MMP3MMP2MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2009-07-30 | — | — | US | claimed |
| WO-2005077937-A1 | SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS TNF INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2009-07-30 | — | — | US | disclosed |
| WO-2005077937-A1 | SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS TNF INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | TNF, TNFRSF1A, TIMP3 | ADAM17 31/4885MMP3 11/4885MMP2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.